Form 4 for CBIO CRESCENT BIOPHARMA, INC.
Accepted 2025-12-08 00:00:00 ET · period of report 2025-12-04 · accession 0001104659-25-119320 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2025-12-08 | 2025-12-04 | CBIO | Harwin Peter Evan | Dir, 10% | P - Purchase | $13.41 | +1.36M | 2.75M | +98% | +$18.24M |
| DI | 2025-12-08 | 2025-12-04 | CBIO | Harwin Peter Evan | Dir, 10% | P - Purchase | $13.41 | +131.4K | 1.77M | +8% | +$1.76M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-12-04 | P | A | 1,360,000 | $13.41 | 2,747,866 | I By Fairmount Healthcare Fund II L.P. | — | — | (F1) Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| 2 | Derivative | Pre-Funded Warrant (Right to Buy) | 2025-12-04 | P | A | 131,434 | $13.41 | 1,768,140 | I By Fairmount Healthcare Fund II L.P. | $0.00 · — to — | 131,434 Ordinary Shares | (F1) Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F2) The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of outstanding shares of common stock of the Issuer immediately after giving effect to such exercise. |